Immutep Ltd. Releases INSIGHT-003 Study Results on Eftilagimod Alpha in First-Line Non-Small Cell Lung Cancer
I'm PortAI, I can summarize articles.
Immutep Ltd. has released updates from its INSIGHT-003 clinical study on eftilagimod alpha, a soluble LAG-3 protein, in combination with first-line chemo-immunotherapy for patients with metastatic non-squamous non-small cell lung cancer. The document details study design, baseline characteristics, safety, tolerability, and efficacy results for the evaluable patient population. The full document is available via a provided link. This news brief is generated by Public Technologies and is for informational purposes only, not financial or legal advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments